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Background: Weight loss in cystic fibrosis (CF) may be associated with altered levels of appetite stimulating peptide ghrelin and the appetite
decreasing peptide leptin. However, prior data on leptin in CF are conflicting, while the data on ghrelin are scarce. We hypothesized that weight
loss in CF is associated with low levels ghrelin and elevated levels of leptin.
Methods: Plasma ghrelin, leptin, TNF-α, IL-1 and IL-6, BMI, fat free mass (FFM), fat mass (FM) were measured in 74 CF adults and 20 controls.
CF subjects were divided into 3 groups based on lung disease: mild (n=19), moderate (n=30) and severe (n=25).
Results: Severe CF patients (% predicted FEV1 27±7; median BMI 21 kg/m2) had significantly elevated ghrelin and decreased leptin compared to
controls and other CF subjects. Ghrelin correlated (r value, p value) with BMI (−0.35,b0.001), FFM (−0.22,b0.05), FM (−0.41,b0.0001), FEV1
(−0.62,b0.001), TNF-α (0.51,b0.0001), IL-1 (0.56,b0.0001), and IL-6 (0.33,b0.01). Leptin correlated (r value, p value)with BMI (0.40,b0.0001), FM
(0.56,b0.0001), FEV1 (0.34,b0.05), IL-1 (−0.51,b0.05) and TNF-α (−0.43,b0.0001). BMI and FEV1 were independent predictors of ghrelin
(−0.35,b0.05;−0.59,b0.001). FMwas a predictor of leptin (0.56,b0.0001). Cytokines were elevated only in severe CF (severe CF vs. controls, pg/ml):
TNF-α (3.4±0.6 vs. 1.2±0.4), IL-1 (3.5±1 vs. 0.2±0.1), IL-6 (17.4±4 vs. 2.4±2).
Conclusions: Elevated ghrelin and decreased leptin levels are a consequence rather than a cause of weight loss in advanced CF.
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In cystic fibrosis (CF) decreased BMI correlates directly with
worsening lung function and is an independent risk factor for
mortality. The mechanisms leading to decreased appetite and
weight loss in CF are not completely understood, but appear to
be associated with altered metabolism and increased activation
of the inflammatory system [1]. Indeed, cytokines such as IL-1,
IL-6 and TNF-α have been implicated in CF and other wasting
conditions associated with inflammation [2,3].
It is now apparent that food intake is mediated in part, by
several peptide hormones through their action on hypothalamic☆ This work was published in abstract form Ped Pulm. 2007; 42:S30 and
presented at the North American CF Conference, Anaheim, 2007.
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doi:10.1016/j.jcf.2008.02.002pathways [4]. Leptin is secreted by adipocytes and has been shown
to decrease food intake [5]. Ghrelin, a potent orexigen, is secreted
by enteroendocrine cells of the stomach and exerts antagonistic
effects on the leptin-induced decrease in food intake [6]. Addi-
tionally, multiple studies have revealed that both leptin and ghrelin
are regulators of the immune system in addition to their effect on
appetite. Leptin, a member of the gp130 family of cytokines, is
regarded as a pro-inflammatory inducer [7], while ghrelin has anti-
inflammatory actions and inhibits inflammatory cytokines [8–10].
Plasma levels of both leptin and ghrelin are altered in starvation
and disease states associated with anorexia [11,12]. However, in
CF, the present data regarding circulating levels of leptin have been
inconsistent with results showing either no difference, compensa-
tory physiological, or pathological changes between CF subjects
and controls [13–17]. The data regarding ghrelin are scarce with
only one study in a small number of CF patients [15]. Therefore, it
remains unclear whether a dysregulation in ghrelin and leptin
secretion exists and whether it contributes to weight loss in CF.d by Elsevier B.V. All rights reserved.
Fig. 1. Plasma ghrelin in normal controls, mild, moderate and severe CF.
* indicates significance to all other groups.
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logical significance, if any, of plasma levels of leptin and ghrelin
in adult CF patients and ascertain whether such levels differ from
controls. We hypothesized that dysregulation of the hormones
leptin and ghrelin would play a role in CF-associated weight loss
and ghrelin levels would be decreased while leptin levels would
be elevated in plasma of CF patients with low BMI.
2. Methods
The protocol was approved by the medical center's Institu-
tional Review Board and all participants gave informed written
consent. We studied 74 CF subjects divided into three groups
based on the severity of their illness. Mild disease (FEV1N75%
predicted, n=19), moderate disease (FEV1 45% to 74% pre-
dicted, n=30), and severe disease (FEV1b45% predicted, n=
25). All CF patients were studied when clinically stable and
without evidence of acute exacerbation as defined by the Cystic
Fibrosis Foundation guidelines [18]. All CF subjects were studied
when weight stable (b5% change within prior 2 months). All CF
patients with pancreatic insufficiency were using supplementary
pancreatic enzymes with meals and had no obvious signs or
clinical symptoms of malabsorption. CF patients who underwent
lung transplantation, were using an appetite stimulant, had edema
or ascites were excluded. None of the CF patients were taking
oral corticosteroids at testing. Patients who were taking oral
corticosteroids were tested a minimum of 4 weeks after stopping.
Twenty healthy control subjects, ten males and ten females
between the ages of 22 and 48 years with BMI in the normal range
(18.5–24.9 kg/m2) were enrolled. All controls were weight stable
within the past 6 months.
Spirometry datawere expressed as%predicted according to the
equations of Knudson et al. [19]. Weight was measured with a
beam scale to the nearest 0.25 kgwith subjects barefoot and lightly
clothed. Height was determined to nearest 0.5 cm, and the BMI
was calculated. Body composition was assessed by bioelectrical
impedance analysis (BIA) (101 Impedance Analyzer; RJL Sys-
tems; Detroit, MI). Fat-free mass (FFM) was estimated using theTable 1
Controls Mild CF Moderate CF Severe CF
n=20 n=19 n=30 n=25
Age years 29(28–31) 25(21–30) 32(26–37) 34(26–48)
Males 10 10 14 15
Females 10 9 16 10
BMI kg/m2 23(21–24) 22.4(21.5–26) 21.9(21–24.7) 21(17–23)*
FFM kg 50.1(30–45) 45(30–44) 40(37–40)* 39(33–41)*
FM kg 20(16–22) 18(15–20) 17(12–30) 10.3(8–16)*†
FEV1 %
predicted
94±9 84±10* 54±9* 27±7*†
FVC %
predicted
97±11 92±12 67±9* 41±9*†
BMI = body mass index, FFM = fat free mass, FM = fat mass.
Normally distributed data are presented as mean±SD. Non-normally distributed
data are presented as median (25–75 percentiles) * significant to control group,
† indicates significance to other CF groups.Segal regression equation [20] and expressed in kg. Fatmass (FM)
was calculated as the difference between total weight minus FFM.
Blood samples were obtained in plastic tubes containing EDTA
between 8 and 10 am after an overnight fast. We measured active
ghrelin levels as this is the physiologically active form of the
peptide. Blood for active ghrelin assay was immediately centri-
fuged at 4 °C, separated, and acidified with 1N HCL then stored at
−80 °C. Plasma active ghrelin levels were measured in duplicates
via a non-radioactive ELISA-based method using anti-human
ghrelin IgG raised against Ser(3)octanoylated ghrelin with no cross
reactivity to des-octanoyl-ghrelin, according to manufacture's ins-
tructions (Millipore, Billerica, MA). Plasma leptin levels were
measured in duplicates using an ELISA-based assay, however
without acidification, based on the capture of human leptin by a
polyclonal rabbit anti-human leptin antibody immobilized on a
microtiter plate according to manufacture's instructions (Millipore,
Billerica, MA).
Plasma levels of TNF-α, IL-1, and Il-6 were analyzed in dupli-
cates via cytometric bead array (CBA) system according to manu-
facture's instructions (BDBioscience, SanDiego, CA). Briefly, this
system relies on bead populations with distinct fluorescence inten-
sities that have been coated with capture antibodies specific for
TNF-α, IL-1 and IL-6 proteins. The bead populations are mixed
together to form theCBA.A flow cytometer (FACSCaliber, Becton
Dickinson) was then used to analyze the light intensity that reflects
the concentration of each cytokine.
3. Data analysis
Datawere tested for normality using theKolmogorov–Smirnov
test using p=0.05 threshold for rejection of normality. Results are
presented as mean± SD for normally distributed variables and as
median with 25 and 75 percentiles for non-normally distributed
results. Data were then analyzed using Sigma Stat 3.5 statistical
software (Systat, Richmond, CA). For normally distributed data,
Fig. 2. Correlation between plasma ghrelin, BMI and FEV1.
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by the Holm–Sidak method for all pair-wise multiple compar-
isons. If data did not follow a normal distribution, the Kruskal–
Wallis one way ANOVA on ranks was used to determine differ-
ences in medians followed by Dunn's post test for all pair-wise
multiple comparisons. Univariate analyses using Spearman corre-
lation coefficient were used to observe the association between
either ghrelin or leptin in plasma and other variables. Those factors
that appeared to be associated with either ghrelin or leptin in the
univariate analysis (pb0.10) were included in a multiple linear
regression model. Backwards selection was used to remove varia-
bles which did not significantly contribute information to the
model, given other factors included in themodel. Linear regression
for ghrelin and leptin were performed separately. A factor was
considered significant at the pb0.05 level.
4. Results
Table 1 describes the characteristics of the four groups (con-
trols, and patients with mild, moderate and severe CF). BMI wasFig. 3. Plasma leptin in normal controls, mild, moderate and severe CF. * indicates
significance to all other groups.maintained in mild and moderate CF, but decreased in severe CF
patients when compared to healthy controls. FFM was preserved
in milder patients; however, FFM was significantly decreased in
moderate and severe CF subjects. FM tended to decrease with
disease severity, but was not statistically significant compared to
controls inmild andmoderateCF. Therewas amarked decrease in
FM in CF patients with severe disease. As a group, CF males had
higher FFM and lower FM than CF females.
4.1. Plasma ghrelin
The plasma ghrelin levels were higher in CF patients with
severe disease compared to controls and to mild and moderate CF
groups. Plasma ghrelin level did not differ between normals, and
patients with mild or moderate disease (Fig. 1). In the CF popu-
lation, plasma ghrelin levels correlated negatively with BMI (r=
−0.35, pb0.001), FFM (r=−0.22, pb0.05), FM (r=−0.41, pb
0.0001), % FEV1 predicted (r=−0.62, pb0.001), and positively
with TNF (r=0.51, pb0.0001), IL-1 (r=0.56, pb0.0001), and
IL-6 (r=0.33, pb0.01). Multiple regression analysis showed that
BMI (pb0.05) and % predicted FEV1 (pb0.001) and were the
only independent predictors of plasmaghrelin. These relationships
are further illustrated in Fig. 2. Gender did not impact on ghrelin
levels.Fig. 4. Correlation between plasma leptin and fat mass (FM).
Table 2
Controls Mild CF Moderate CF Severe CF
TNF-α 1.2±0.4 1.2±0.5 1.5±0.5 3.4±0.6⁎†
IL-1 0.2±0.1 0.4±0.8 1.5±0.8 3.5±1⁎†
IL-6 2.4±2 3.8±3 7.5±2 17.4±4⁎†
Cytokine plasma levels (pg/ml); ⁎ significant to control group, † indicates
significance to other CF groups.
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The plasma leptin levels were lower in severe CF patients
when compared to controls and those with mild and moderate
disease (Fig. 3). Leptin level did not differ between controls and
CF patients with mild and moderate disease. Plasma leptin level
correlated with BMI (r=0.40, pb0.0001), FM (r=0.56, pb
0.0001), FEV1 (r=0.34, pb0.05) and negatively with IL-1 (r=
−0.51, pb0.05) and TNF (r=−0.43, pb0.0001), but not with
IL-6. Multiple regression analysis showed that FM was the only
independent predictor of plasma leptin levels (pb0.01). This
relationship between leptin and FM is further illustrated in
Fig. 4. Females had higher leptin levels than males.
4.3. Plasma cytokines
The levels of all IL-1 beta, TNF-α and IL-6 were higher in
CF patients with severe disease compared to the other three
groups (Table 2).
5. Discussion
Appetite regulation is critical for the survival of any species;
because of this, a complex circuitry of compensatory and over-
lapping mechanisms has evolved to protect the host in periods of
starvation. Indeed, starvation leads to a compensatory increase in
circulating ghrelin [21] and a decrease in leptin levels [22]. How-
ever, diseases associated with anorexia differ from starvation as
they are characterized by increased metabolic rate and an aberrant
inflammatory response.Moreover, compensatorymechanisms that
should promote increased caloric intake may either be maladaptive
or not function properly [23].
We demonstrate that 1) plasma ghrelin is elevated only in
severe CF. Ghrelin levels correlate negatively with lung function
and BMI, and positively with inflammatory cytokines, 2) plasma
leptin is decreased only in advanced CF and correlates positively
with BMI and % predicted FEV1 and negatively with cytokines.
We also show that FM was an independent predictor for leptin,
while BMI and FEV1 were independent predictors for ghrelin.
Thus, the changes in ghrelin and leptin levels in severe CF indicate
compensatory response to the decreased BMI and FM. Whether,
there exists an altered sensitivity to leptin and ghrelin in advanced
CF or whether there are other aspects of neurohumoral dys-
function is presently unknown.
Five prior studies measured leptin in CF [13–17]. Two found
increased leptin in CF children [14,15], indicating that dys-
regulation of leptin synthesis exists, and higher leptin levels
contribute to anorexia, poor weight gain and growth. One study
showed decreased leptin in 26 CF children whose lung functionwas not studied, and this was associated with clinical activity
and decreased fat mass [17]. Two studies found no difference in
leptin between CF and controls [13,16]. The reasons for such
discrepancies are not clear, and direct comparisons are difficult
to make as prior studies included small number of patients, and
different CF and control populations. Moreover, the majority of
studies assessed children or adolescents [14–17] who have dif-
ferent body composition compared to adults and in whom ghrelin
and leptin could have different significance. Unlike our study, no
prior study examined severe CF subjects.
To our knowledge, only one study [15] examined ghrelin levels
in CF. In a group of only 14 CF adolescents with lower BMI and
body fat compared to controls; ghrelin levels were lower in the CF
males, with no differences in females. Unfortunately, this study
did not assess lung function. Plasma ghrelin was also assessed in
underweight emphysema subjects and found to be elevated, indi-
cating a physiological compensatory mechanism to poor nutri-
tional status [24].
We did not demonstrate elevated levels of TNF-α, IL-1 beta and
IL-6 in CF subjects with mild and moderate disease whose BMI
did not differ from controls. In severe CF BMI decreased along
with an increase in inflammatory mediators generally associated
with anorexia. Interestingly, ghrelin has anti-inflammatory [8–10],
while leptin has pro-inflammatory effects [7]. Thus, the increased
ghrelin along with decreased leptin in severe CF would be ex-
pected to attenuate the elevated inflammatory response in ad-
vanced CF. However, in severe CF, our data indicate that TNF-α,
IL-1 beta and IL-6 were elevated, and not reduced by any immune
modulating effects of elevated ghrelin or decreased leptin.
In the present study, body composition analysis showed de-
clining FFM that became significant in moderate and advanced
CF. Assessment of body composition using BIA may be less
precise than dual-energy X-ray absorptiometry (DEXA) scan-
ning. Nevertheless, prior studies have shown good correlation
between DEXA and BIA making BIA acceptable for the assess-
ment of body composition in CF [25, 26]. Ionescu et al suggested
that persistent inflammatory activation accounted for FFM deple-
tion in moderate CF [25]. Our results show that cytokines were
elevated only in severe CF. Thus, these cytokines, by themselves
do not account for decreased in FFM in moderate CF. The etio-
logy of decreased FFM in moderate CF is likely multifactorial,
and this study was not designed to investigate such mechanisms.
FM decreased in severe CF patients who demonstrated a 50%
decrease compared to controls. This decrease in FM in advanced
CF could account for decreased in leptin levels as it is produced
mainly by adipose tissue. In fact FMwas an independent predictor
of plasma leptin levels. Once again, it would appear that the lower
leptin levels in severe CF are a response to, rather than cause of
FM depletion.
In the present study, % predicted FEV1 was an independent
predictor of plasma ghrelin levels. Thus, ghrelin may be asso-
ciated with decreased lung function in advanced CF. While this
correlation does not imply cause and effect; ghrelin is expressed in
the lung [27]. The present study did not assess tissue ghrelin
levels. Further studies are needed to determine whether the levels,
and possibly the effects of ghrelin depend on the compartment in
which it is measured.
402 R.I. Cohen et al. / Journal of Cystic Fibrosis 7 (2008) 398–402We studied CF patients when they were clinically and weight
stable. Levels of ghrelin and leptin could change during an exa-
cerbation. Whether such changes could influence the decreased
appetite associated with CF exacerbations is presently unknown.
We conclude that plasma levels of the anorexigenic peptide
leptin were decreased in patients with severe CF and decreased
BMI exhibiting both FFM and FM depletion.We conclude further
that levels of the orexigenic peptide ghrelin were elevated in these
patients. These changes appear to be a consequence rather than
a cause of the anorexic, pro-inflammatory state in patients with
advanced CF.
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